Equashield and SynTronic Introduce Award-Winning Closed System Transfer Devices to Protect Healthcare Workers in Brazil

Expansion of Activities in Latin America Highlights Leading Device Maker’s Ongoing Commitment to Supporting Safe Handling and Administration of Hazardous Drugs


PORT WASHINGTON, New York – November 19, 2020 – Equashield (, a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today its increased expansion in Latin America through its partnership with SynTronic Hospitalar, a leading national distributor of medical and technical solutions, to introduce Equashield products to Brazil.

Through SynTronic, Equashield products are now available to public and private Brazilian healthcare facilities, including hospitals, compounding facilities and infusion centers. This includes both Equashield’s flagship Closed System Transfer Device, as well as EQUASHIELD® Pro, the world’s first CSTD-enabled automated compounding system. The expansion follows the previous introduction of Equashield’s products to healthcare organizations in Chile and Panama.

“As recent events have shown, it is essential that healthcare workers are provided the necessary protective equipment that enables them to carry out their lifesaving roles safely and efficiently,” said Adi Shor, VP International Sales for Equashield. “Compounding and administrating hazardous drugs without effective closed systems presents a clear and present danger to hospital and pharmacy staff. We are delighted to partner with SynTronic, which shares our commitment to protecting healthcare workers in Brazil from the inherent dangers of handling hazardous drugs.”

The introduction of Equashield to Brazil follows the current discussions at institutions that closed systems be implemented to ensure the safe handling and compounding of hazardous drugs, and the additional NR32 guidelines which state that employers must provide safety devices that minimize the generation of aerosols during handling and administration of antineoplastic chemotherapy medications.

“We are pleased to introduce Equashield’s specialized CSTD solutions, which represent the gold standard for protecting healthcare workers handling hazardous drugs, to Brazilian healthcare and compounding facilities,” said Regiane Santos, Managing Director of SynTronic. “While current publications do recommend the use of CSTDs, when available, for handling hazardous drugs, too many healthcare workers are at risk of exposure due to a lack of awareness of the need for fully closed systems. Educating workers about the risks of exposure and the protection provided by effective CSTDs will be essential as we begin introducing Equashield’s leading system to Brazil.”

# # #

About SynTronic Hospitalar

SynTronic Hospitalar is a leading provider of advanced medical devices, with offices in São Paulo, Brazil. SynTronic professionals have extensive knowledge of the Brazilian market, with over 25 years of accumulated experience making important contributions to the fields of oncology, infusion therapies, pharmacy, compounding centers and home therapies.

For more information:

Follow SynTronic on LinkedIn: SynTronic Hospitalar  and  Instagram: syntronichospitalar


About Equashield

Equashield is a leading provider of manual and automated solutions for the compounding and administration of hazardous drugs. Equashield’s product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system-enabled Automated Pharmacy Compounding System. Equashield’s CSTD is clinically proven to protect healthcare professionals from hazardous drug exposure. EQUASHIELD II covers more routes of exposure than alternative systems and has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. Studies have shown Equashield’s CSTD as faster to deploy and easier to use than competing systems. Used by hundreds of hospitals and clinics around the world, EQUASHIELD II is CE marked and substantiated by the FDA for preventing microbial ingress for up to seven days.

For more information:

Follow Equashield on LinkedInTwitter and Facebook.


Media Contact:
Finn Partners for Equashield
Danny Sudwarts